Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.35 USD
0.00 (-0.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.35 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Adial Pharmaceuticals, Inc.'s return on equity, or ROE, is -191.31% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ADIL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ADIL 0.35 0.00(-0.43%)
Will ADIL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Other News for ADIL
Is ADIL likely to continue higher? Stochastic Buy Signal shows up after rising 1.3%
Narrow Range Bar appears for ADIL after 0.0% move
MACD Bullish Signal Line Cross appears for ADIL after 0.86% move
Adial Pharmaceuticals Advances AD04 with FDA Support
Adial Pharmaceuticals (ADIL) Moves Forward with FDA Guidance on AD04 Phase 3 Trial